Phase-sensitive polymer-based controlled delivery systems of leuprolide acetate: In vitro release, biocompatibility, and in vivo absorption in rabbits

International Journal of Pharmaceutics

Volumn 328, Issue 1 SPEC. ISS., 2007, Pages 42-48

  Singh, Somnath ^a   Singh, Jagdish ^b  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^b NORTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

Biocompatibility; Controlled release; In vivo absorption; Leuprolide acetate; Phase sensitive polymer; Rabbits

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BENZYL ALCOHOL; BENZYL BENZOATE; DRUG CARRIER; LEUPRORELIN; ORGANIC SOLVENT; POLYLACTIC ACID; POLYMER; TESTOSTERONE;

ANIMAL EXPERIMENT; ARTICLE; BIOCOMPATIBILITY; BLOOD SAMPLING; CASTRATION; CELL VIABILITY; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CULTURE MEDIUM; DILUTION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOASSAY; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; STATISTICAL SIGNIFICANCE; TESTOSTERONE BLOOD LEVEL;

EID: 35348875308     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.07.051     Document Type: Article

References (24)

1. Adjei A., Sundberg D., Miller D., and Chun A. Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. Pharm. Res. 9 (1992) 244-249
2. Briken P., Hill A., and Berner W. Pharmacotherapy of paraphilias with long-acting agonists of luteinizing hormone-releasing hormone: a systematic review. J. Clin. Psychiatry 64 (2003) 890-897
3. Brodbeck K.J., DesNoyer J.R., and McHugh A.J. Phase inversion dynamics of PLGA solutions related to drug delivery. Part II. The role of solution thermodynamics and bath-side mass transfer. J. Cont. Rel. 62 (1999) 333-344
4. Casadesus G., Zhu X., Atwood C.S., Webber K.M., Perry G., Bowen R.L., and Smith M.A. Beyond estrogen: targeting gonadotropin hormones in the treatment of Alzheimer's disease. Curr. Drug Targets CNS Neurol. Disord. 3 (2004) 281-285
5. Chandrashekhar B.L., Madril D., Tow K., Balliu C., and Bawa R.S. Sustained release of leuprolide acetate from an in-situ forming biodegradable polymeric implant as the delivery vehicle. Proc. Int. Symp. Control. Rel. Bioact. Mater. 28 (2001) abst # 6406
6. Cleland J.L. Injectable gels for local and systemic delivery of proteins. Proc. Int. Symp. Control. Rel. Bioact. Mater. 28 (2001) abst # 0221
7. Croom K.F., and Perry C.M. Leuprolide acetate once yearly subcutaneous implant in advanced prostate cancer. Am. J. Cancer 2 (2003) 57-64
8. Duenas E., Okumu F., Daugherty A., and Cleland J.L. Sustained delivery of rhVEGF from a novel injectable liquid, PLAD. Proc. Int. Symp. Control Rel. Bioact. Mater. 28 (2001) abst # 6216
9. Eliaz R.E., and Kost J. Characterization of a polymeric PLGA-injectable implant delivery system for the controlled release of proteins. J. Biomed. Mater. Res. 50 (2000) 388-396
10. Hatefi A., and Amsden B. Biodegradable injectable in situ forming drug delivery systems. J. Control Rel. 80 (2002) 9-28
11. Ignatius A.A., and Claes L.E. In vitro biocompatibility of bioresorbable polymers: poly(l, dl-lactide) and poly(l-lactide-co-glycolide). Biomaterials 17 (1996) 831-839
12. Marks L.S. Luteinizing hormone-releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implant. Urology 62 (2003) 36-42
13. Meethal S.V., Smith M.A., Bowen R.I., and Atwood C.S. The gonadotropin connection in Alzheimer's disease. Endocrine 26 (2005) 317-326
14. Okumu F.W., Daugherty A., Dao L., Filder P.J., Brooks D., Sane S., and Cleland J.L. Sustained delivery of growth hormone from a novel injectable liquid, PLAD. Proc. Int. Symp. Control. Rel. Bioact. Mater. 28 (2001) abst # 6210
15. Perez-Marrero R., and Tyler R.C. A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer. Expert Opin. Pharmacother. 5 (2004) 447-457
16. Periti P., Mazzei T., and Mini E. Clinical pharmacokinetic of depot leuprolide. Clin. Pharmacokin. 41 (2002) 485-504
17. Persad R. Leuprorelin acetate in prostate cancer: a European update. Int. J. Clin. Pract. 56 (2002) 389-396
18. Physicians' Desk Reference. Lupron Depot-4 Month 30 mg (TAP) (2002), Medical Economics Company, Inc., Montvale, NJ pp. 3289-3291
19. Ravivarapu H.B., Moyer K.L., and Dunn R.L. Sustained activity and release of leuprolide acetate from an in situ forming polymeric implant. AAPS PharmSciTech 1 1 (2000) article 1
20. Saroglou V., Hatziantoniou S., Smyrniotakis M., Kyrikou I., Mayromoustakos T., Zompra A., Magafa V., Cordopatis P., and Demetzos C. Synthesis, liposomal formulation and thermal effects on phospholipids bilayers of leuprolide. J. Pept. Sci. 12 (2006) 43-50
21. Shahiwala A., and Misra A. A preliminary pharmacokinetic study of liposomal leuprolide dry powder inhaler: a technical note. AAPS PharmSciTech 6 (2005) E482-E486
22. Singh J., Rastogi S.K., Singh S.N., and Bhatia J.S. Quantification of leuprolide acetate by high performance liquid chromatography. J. Liq. Chromogr. Related Technol. 23 (2000) 3023-3031
23. Sohier J., van Dijkhuizen-Radersma R., de Groot K., and Bezemer J.M. Release of small water-soluble drugs from multiblock copolymer microspheres: a feasibility study. Eur. J. Pharm. Biopharm. 55 (2003) 221-228
24. Zheng J.Y., and Fulu M. Decrease of genital organ weights and plasma testosterone levels in rats following oral administration of leuprolide microemulsion. Int. J. Pharm. 307 (2006) 209-215